Targeting Micro-environmental Pathways by PROTACs As a Therapeutic Strategy

Overview

Journal Semin Cancer Biol

Specialty Oncology

Date 2022 Jul 7

PMID 35798235

Authors

Jing Liu

Yunhua Peng

Hiroyuki Inuzuka

Wenyi Wei

Affiliations

Soon will be listed here.

Abstract

Tumor microenvironment (TME) composes of multiple cell types and non-cellular components, which supports the proliferation, metastasis and immune surveillance evasion of tumor cells, as well as accounts for the resistance to therapies. Therefore, therapeutic strategies using small molecule inhibitors (SMIs) and antibodies to block potential targets in TME are practical for cancer treatment. Targeted protein degradation using PROteolysis-TArgeting Chimera (PROTAC) technic has several advantages over traditional SMIs and antibodies, including overcoming drug resistance. Thus many PROTACs are currently under development for cancer treatment. In this review, we summarize the recent progress of PROTAC development that target TME pathways and propose the potential direction of future PROTAC technique to advance as novel cancer treatment options.

Citing Articles

Deciphering the Prognostic and Therapeutic Significance of Cell Cycle Regulator CENPF: A Potential Biomarker of Prognosis and Immune Microenvironment for Patients with Liposarcoma.

Chen J, Lian Y, Zhao B, Han J, Li X, Wu J Int J Mol Sci. 2023; 24(8).

PMID: 37108172 PMC: 10139200. DOI: 10.3390/ijms24087010.

Exploiting E3 ubiquitin ligases to reeducate the tumor microenvironment for cancer therapy.

Li X, Zhao Z, Yu X, Xia Q, Zhou P, Wang S Exp Hematol Oncol. 2023; 12(1):34.

PMID: 36998063 PMC: 10061905. DOI: 10.1186/s40164-023-00394-2.

Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy.

Peng Y, Liu J, Inuzuka H, Wei W J Biol Chem. 2023; 299(4):104572.

PMID: 36870680 PMC: 10050664. DOI: 10.1016/j.jbc.2023.104572.

Adriamycin-loaded exosome with anti-CD20 aptamers selectively suppresses human CD20+ melanoma stem cells.

Chen H, Jiang Y, Li X Skin Res Technol. 2023; 29(1):e13259.

PMID: 36704890 PMC: 9838758. DOI: 10.1111/srt.13259.

References

Engelhardt H, Bose D, Petronczki M, Scharn D, Bader G, Baum A . Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors. J Med Chem. 2019; 62(22):10272-10293. DOI: 10.1021/acs.jmedchem.9b01169. View

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Venton G, Perez-Alea M, Baier C, Fournet G, Quash G, Labiad Y . Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors. Blood Cancer J. 2016; 6(9):e469. PMC: 5056970. DOI: 10.1038/bcj.2016.78. View

Donovan K, Ferguson F, Bushman J, Eleuteri N, Bhunia D, Ryu S . Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell. 2020; 183(6):1714-1731.e10. PMC: 10294644. DOI: 10.1016/j.cell.2020.10.038. View

Piya S, Yang Y, Bhattacharya S, Sharma P, Ma H, Mu H . Targeting the NOTCH1-MYC-CD44 axis in leukemia-initiating cells in T-ALL. Leukemia. 2022; 36(5):1261-1273. PMC: 9061299. DOI: 10.1038/s41375-022-01516-1. View

Yang K, Zhao Y, Nie X, Wu H, Wang B, Almodovar-Rivera C . A Cell-Based Target Engagement Assay for the Identification of Cereblon E3 Ubiquitin Ligase Ligands and Their Application in HDAC6 Degraders. Cell Chem Biol. 2020; 27(7):866-876.e8. PMC: 7368820. DOI: 10.1016/j.chembiol.2020.04.008. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Wu X, Yang X, Xiong Y, Li R, Ito T, Ahmed T . Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders. Nat Cancer. 2021; 2(4):429-443. PMC: 8462800. DOI: 10.1038/s43018-021-00174-z. View

Zorba A, Nguyen C, Xu Y, Starr J, Borzilleri K, Smith J . Delineating the role of cooperativity in the design of potent PROTACs for BTK. Proc Natl Acad Sci U S A. 2018; 115(31):E7285-E7292. PMC: 6077745. DOI: 10.1073/pnas.1803662115. View

10.

Sagiv-Barfi I, Kohrt H, Czerwinski D, Ng P, Chang B, Levy R . Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A. 2015; 112(9):E966-72. PMC: 4352777. DOI: 10.1073/pnas.1500712112. View

11.

Liu Z, Hu X, Wang Q, Wu X, Zhang Q, Wei W . Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2. J Med Chem. 2021; 64(5):2829-2848. DOI: 10.1021/acs.jmedchem.0c02234. View

12.

Jin X, Ding D, Yan Y, Li H, Wang B, Ma L . Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. Mol Cell. 2018; 73(1):22-35.e6. PMC: 8968458. DOI: 10.1016/j.molcel.2018.10.034. View

13.

Martin V, Chiriaco C, Modica C, Acquadro A, Cortese M, Galimi F . Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours. Br J Cancer. 2019; 120(5):527-536. PMC: 6461865. DOI: 10.1038/s41416-018-0315-3. View

14.

Jang J, To C, De Clercq D, Park E, Ponthier C, Shin B . Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations. Angew Chem Int Ed Engl. 2020; 59(34):14481-14489. PMC: 7686272. DOI: 10.1002/anie.202003500. View

15.

Vannam R, Sayilgan J, Ojeda S, Karakyriakou B, Hu E, Kreuzer J . Targeted degradation of the enhancer lysine acetyltransferases CBP and p300. Cell Chem Biol. 2021; 28(4):503-514.e12. DOI: 10.1016/j.chembiol.2020.12.004. View

16.

Jin M, Jin W . The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct Target Ther. 2020; 5(1):166. PMC: 7447642. DOI: 10.1038/s41392-020-00280-x. View

17.

Zhou B, Hu J, Xu F, Chen Z, Bai L, Fernandez-Salas E . Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression. J Med Chem. 2017; 61(2):462-481. PMC: 5788414. DOI: 10.1021/acs.jmedchem.6b01816. View

18.

Chertow G, Pergola P, Farag Y, Agarwal R, Arnold S, Bako G . Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021; 384(17):1589-1600. DOI: 10.1056/NEJMoa2035938. View

19.

Xiao Y, Zou Q, Xie X, Liu T, Li H, Jie Z . The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity. J Exp Med. 2017; 214(5):1493-1507. PMC: 5413337. DOI: 10.1084/jem.20161524. View

20.

Kalucka J, de Rooij L, Goveia J, Rohlenova K, Dumas S, Meta E . Single-Cell Transcriptome Atlas of Murine Endothelial Cells. Cell. 2020; 180(4):764-779.e20. DOI: 10.1016/j.cell.2020.01.015. View